XML 34 R20.htm IDEA: XBRL DOCUMENT

Loss Per Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Note 14 — Loss Per Share

The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows:


		Year Ended December 31,
		2020				2019
Numerator
Net loss - before noncontrolling interest		$	(35,888	)		$	(17,268	)
Net loss attributable to noncontrolling interest			1,612				811
Net loss - as reported, attributable to PAVmed Inc.		$	(34,276	)		$	(16,457	)

Series B Convertible Preferred Stock dividends – earned⁽¹⁾		$	(287	)		$	(270	)

Net loss attributable to PAVmed Inc. common stockholders		$	(34,563	)		$	(16,727	)

Denominator
Weighted average common shares outstanding, basic and diluted⁽²⁾			47,432,115				30,197,458

Loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.		$	(0.72	)		$	(0.54	)
Net loss attributable to PAVmed Inc. common stockholders		$	(0.73	)		$	(0.55	)

The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows:

		December 31,
		2020				2019
PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards			8,215,195				5,903,529
Unit purchase options - as to shares of common stock			53,000				53,000
Unit purchase options - as to shares underlying Series Z Warrants			53,000				53,000
Series Z Warrants			16,814,939				16,815,039
Series W Warrants			381,818				381,818
Series B Convertible Preferred Stock⁽³⁾			1,228,075				1,158,209
Total			26,746,027				24,364,595

⁽¹⁾	The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented.

⁽²⁾	Basic weighted-average number of shares of common stock outstanding for the years ended December 31, 2020 and 2019 include the shares of the Company issued and outstanding during the years ended December 31, 2020 and December 31, 2019, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.

⁽³⁾	If converted, at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in a corresponding number of additional outstanding shares of common stock of the Company.